Davis's Drug Guide
** Update Information **
Latest Update
This resource was last updated on:2019-7-24
New topics:
- abaloparatide
- amlodipine/celecoxib
- apalutamide
- avatrombopag
- bictegravir/emtricitabine/tenofovir alafenamide
- burosumab
- cerliponase alfa
- encorafenib
- erenumab
- lamivudine/tenofovir disoproxil fumarate
- lofexidine
- sodium zirconium cyclosilicate
- tildrakizumab
Changed topics:
- acalabrutinib
- adapalene
- angiotensin II
- apixaban
- ARIPiprazole
- atezolizumab
- avelumab
- belimumab
- benralizumab
- benznidazole
- bevacizumab
- calcium acetate
- calcium citrate
- captopril
- carfilzomib
- cariprazine
- carteolol
- copanlisib
- darunavir/cobicistat
- daunorubicin/cytarabine liposomal
- defibrotide
- deflazacort
- deutetrabenazine
- dexlansoprazole
- doxycycline†
- dupilumab
- durvalumab
- elbasvir/grazoprevir
- eluxadoline
- ephedrine
- ertugliflozin
- eteplirsen
- fentaNYL (transdermal)
- ferric pyrophosphate citrate
- fingolimod
- flupentixol
- fluticasone/umeclidinium/vilanterol
- fulvestrant
- gabapentin
- glycopyrrolate, oral inhalation
- glycopyrrolate/formoterol
- golimumab
- guselkumab
- hydrogen peroxide
- hydroxyurea
- ibrutinib
- ibuprofen
- imatinib
- indacaterol/glycopyrrolate
- inFLIXimab
- inotuzumab ozogamicin
- insulin aspart
- insulin degludec
- insulin glargine
- insulin glargine/lixisenatide
- insulin lispro, rDNA origin
- letermovir
- lovage
- macimorelin
- mechlorethamine
- methIMAzole
- mipomersen
- naloxegol
- natalizumab
- niCARdipine
- nilotinib
- nintedanib
- nivolumab
- nusinersen
- obeticholic acid
- obiltoxaximab
- obinutuzumab
- olaparib
- olaratumab
- omacetaxine
- ombitasvir/paritaprevir/ritonavir
- ombitasvir/paritaprevir/ritonavir/dasabuvir
- onabotulinumtoxinA
- osimertinib
- OXcarbazepine
- ozenoxacin
- palbociclib
- paliperidone
- pantoprazole
- PAZOPanib
- pembrolizumab
- PENTobarbital
- peramivir
- perampanel
- phytonadione
- pioglitazone
- PONATinib
- posaconazole
- prasterone
- prasugrel
- pregabalin
- RABEprazole
- raltegravir
- ranibizumab
- remifentanil
- rifAMPin
- rifAXIMin
- ritonavir
- rituximab/hyaluronidase
- rivaroxaban
- secnidazole
- semaglutide
- sodium sulfate/potassium sulfate/magnesium sulfate
- telotristat ethyl
- timolol†
- vestronidase alfa-vjbk
** Update Information ** is a sample topic from the Davis's Drug Guide.
To view other topics, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Complete Product Information.
Citation
Quiring, Courtney, et al. "** Update Information **" Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50998/all/___Update_Information___.
Quiring C, Sanoski CA, Vallerand AH. ** Update Information ** Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50998/all/___Update_Information___. Accessed October 20, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). ** Update Information ** In Davis's Drug Guide. Available from https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50998/all/___Update_Information___
Quiring C, Sanoski CA, Vallerand AH. ** Update Information ** [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 October 20]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50998/all/___Update_Information___.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - ** Update Information **
ID - 50998
A1 - Quiring,Courtney,
AU - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50998/all/___Update_Information___
PB - F.A. Davis Company
ET - 16
DB - Pediatrics Central
DP - Unbound Medicine
ER -